K. Rowland

Characteristics of New Biologic Users Among the Moderate-to-Severe Psoriasis Population—Retrospective Cohort Study Leveraging the Modernizing Medicine Data Services Database

T. Fitzgerald, Mobolaji O Olurinde, A. Near, 2022, Dermatology and Therapy.

Demographics, Disease Characteristics, and Patient-Reported Outcomes Among Patients with Psoriasis Who Initiated Guselkumab in CorEvitas’ Psoriasis Registry

T. Fitzgerald, J. Walsh, J. Merola, 2021, Dermatology and Therapy.

Effectiveness of Guselkumab Therapy among Patients with Plaque Psoriasis with Baseline IGA Score ≥ 2 in the CorEvitas Psoriasis Registry

T. Fitzgerald, R. McLean, K. Callis Duffin, 2022, Dermatology and Therapy.

Real-World Effectiveness of 9–12 Months of Guselkumab Therapy among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry

T. Fitzgerald, R. McLean, K. Callis Duffin, 2022, Dermatology and Therapy.

The Effectiveness of Guselkumab by BMI Category Among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry

T. Fitzgerald, A. Armstrong, R. McLean, 2023, Advances in therapy.

Safety of Guselkumab Treatment for up to 5 Years in Patients With Moderate-to-Severe Psoriasis: Pooled Analyses Across Seven Clinical Trials With Greater Than 8600 Patient-Years of Exposure.

M. Lebwohl, Y. You, J. Merola, 2023, British Journal of Dermatology.

Malignancy Rates Through 5 Years of Follow-up in Patients With Moderate-to-Severe Psoriasis Treated With Guselkumab: Pooled Results From the VOYAGE 1 and VOYAGE 2 Trials.

M. Lebwohl, K. Papp, P. Foley, 2023, Journal of American Academy of Dermatology.

Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis

M. Lebwohl, A. Deodhar, S. Chakravarty, 2023, Drug safety.